Setidegrasib

Setidegrasib
Clinical data
Other names	ASP-3082
Identifiers
	IUPAC name (2S,4R)-1-[(2S)-2-[4-[4-[[6-cyclopropyl-4-[(1S,4S)-2,5-diazabicyclo[2.2.1]heptan-2-yl]-7-(6-fluoro-5-methyl-1H-indazol-4-yl)-2-(oxan-4-yloxy)quinazolin-8-yl]oxymethyl]phenyl]triazol-1-yl]-3-methylbutanoyl]-4-hydroxy-N-[(1R)-2-hydroxy-1-[4-(4-methyl-1,3-thiazol-5-yl)phenyl]ethyl]pyrrolidine-2-carboxamide;
CAS Number	2821793-99-9;
PubChem CID	164875418;
DrugBank	DB21670;
ChemSpider	128942434;
UNII	3NQ4ME292X;
ChEBI	CHEBI:760090;
ChEMBL	ChEMBL6068173;
PDB ligand	A1L66 (PDBe, RCSB PDB);
Chemical and physical data
Formula	C60H65FN12O7S
Molar mass	1117.32 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC1=C(C=C2C(=C1C3=C(C=C4C(=C3OCC5=CC=C(C=C5)C6=CN(N=N6)[C@@H](C(C)C)C(=O)N7C[C@@H](C[C@H]7C(=O)N[C@@H](CO)C8=CC=C(C=C8)C9=C(N=CS9)C)O)N=C(N=C4N1C[C@@H]3C[C@H]1CN3)OC1CCOCC1)C1CC1)C=NN2)F;
	InChI InChI=InChI=1S/C60H65FN12O7S/c1-31(2)54(59(77)72-26-41(75)20-50(72)58(76)65-49(28-74)37-11-13-38(14-12-37)56-33(4)63-30-81-56)73-27-48(69-70-73)36-7-5-34(6-8-36)29-79-55-52(51-32(3)46(61)22-47-45(51)24-64-68-47)43(35-9-10-35)21-44-53(55)66-60(80-42-15-17-78-18-16-42)67-57(44)71-25-39-19-40(71)23-62-39/h5-8,11-14,21-22,24,27,30-31,35,39-42,49-50,54,62,74-75H,9-10,15-20,23,25-26,28-29H2,1-4H3,(H,64,68)(H,65,76)/t39-,40-,41+,49-,50-,54-/m0/s1; Key:XXWMEQMGQNHRAF-WFJRNIGCSA-N;

Setidegrasib is an investigational new drug that is being evaluated by Astellas Pharma for the treatment of solid tumors.^[1] It is an PROTACs degrader of the KRAS protein harboring a G12D mutation.^[1]^[2]^[3]

Clinical trials

Setidegrasib in combination with either FOLFIRINOX or NALIRIFOX chemotherapy is currently in phase 3 clinical trials for the treatment of pancreatic cancer.^[4]

1 2 "Setidegrasib - Astellas Pharma". AdisInsight. Springer Nature Switzerland AG.
↑ Zhang YB, Fu JW, Liu Y, Wu RL, Liang YT, Zhang WH, et al. (July 2026). "Targeted protein degradation: bridging chemical biology and clinical translation". Acta Pharmacologica Sinica. doi:10.1038/s41401-026-01861-2. PMID 42414544.
↑ Yoshinari T, Nagashima T, Ishioka H, Inamura K, Nishizono Y, Tasaki M, et al. (August 2025). "Discovery of KRAS(G12D) selective degrader ASP3082". Nature Communications Chemistry. 8 (1) 254. Bibcode:2025CmChe...8..254Y. doi:10.1038/s42004-025-01662-4. PMC 12375097. PMID 40849515.
↑ Clinical trial number NCT07409272 for "A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given with either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People with Pancreatic Cancer" at ClinicalTrials.gov

This pharmacology-related article is a stub. You can help Wikipedia by adding missing information.